No abstract

La psicosis en los pacientes con enfermedad de Parkinson es frecuente, a la fecha se carece de instrumentos clínicos adecuados para su evaluación. Objetivo: determinar la utilidad de dos instrumentos clínicos en la evaluación de la psicosis en pacientes mexicanos con enfermedad de Parkinson. Material y métodos: se incluyeron pacientes con diagnóstico de enfermedad de Parkinson; así como de psicosis. Se aplicaron los instrumentos clínicos TUHARS y UM-PDHQ; comparados con la escala de síntomas positivos y negativos. Resultados: ambos instrumentos presentaron una consistencia interna baja (

Objective:The aim of this study was to assess the association between dopaminergic-induced complications and satisfaction with life in patients with Parkinson's disease. Methods: A cross-sectional study was carried out. Subjects were recruited from two movement disorders clinics in Mexico, from May to October 2019. Dopaminergic drug-induced complications were assessed with the movement disorders society -unified Parkinson's disease rating scale items 4.1-4.5 where satisfaction with life scale score was used as the outcome variable. Correlation coefficients were utilized. Results: Sixty-eight patients were included in the study. The mean satisfaction with life scale score was 25.7 (SD = 5.3), with 66.1% of them scoring higher than average scores. Age at diagnosis (rs = 0.256, p = 0.035), education (rs = 0.240, p = 0.048), geographic region (r2 = 0.180, p = 0.034), movement disorders society -unified Parkinson's disease rating scale part I (rs = −0.378, p = 0.002) and II (rs = −0.280, p = 0.021), and Hoehn and Yahr stage (rs = −0.295, p = 0.015) were significantly correlated with satisfaction with life scale scores. Partial correlation coefficient analysis revealed a statistically significant but moderate correlation between motor fluctuations and satisfaction with life scale scores (rs = −0.408, p = 0.001). No significant correlation was observed with dyskinesias. Conclusions: Motor fluctuations but not dyskinesias have a detrimental effect on patients' life satisfaction. Strategies to reduce motor fluctuations and better understanding the contribution of these to patients' lives may help minimize the negative impact of these complications on patients with PD.

Objective: This study aims to identify the possible factors that delay the time-to-diagnosis of Huntington's disease (HD). Methods: A cross-sectional study in HD patients was carried out. Variables registered were CAG repeats, age of onset, primary symptom at onset, age of molecular diagnosis, and time-to-diagnosis, among others. Results: 107 patients (50.5% female) with a mean age of 49 ± 12.8 years (y) were included in the study. . Mean age of onset, mean age of molecular diagnosis, and mean time-to-diagnosis were 39 ± 12.9, 45.1 ± 12.1, and 6.4 ± 6.4 years, respectively. In the comparative analysis, the neuropsychiatric-and the young-onset groups had a longer time-to-diagnosis than the motor-and typical-onset groups (p = 0.02 and p < 0.01, respectively). In the linear regression analysis, neuropsychiatric-and young-onset were independent risk factors. Conclusions: Delayed diagnosis showed relation to neuropsychiatric-and early-onset in HD.

Objective: This study aims to identify whether type 2 diabetes mellitus (T2DM) impacts the age of Parkinson's disease (PD) onset. Methods: Consecutive people living with PD (PwP) with 2-4 years of disease duration were included and categorized according to the presence of T2DM. A 2:1 ratio randomization from the non-DM sample was performed. T2DM diagnosis was defined by a positive personal history of T2DM recorded in the medical files or reported by the subject, or the use of a hypoglycemic drug for glycemic control. A clinical assessment including the Movement Disorder Society Unified Parkinson's disease rating scale and the Hoehn and Yahr was performed by a movement disorders specialist. Results: One hundred and twenty-four non-T2DM PwP and 62 PwP with T2DM (PD-DM) were included in the study. No statistically significant differences between groups were found in motor and non-motor scores nor in disease duration. The mean age of the whole sample was 63.4 ± 11.9 years, with a mean PD duration of 3.4 ± 0.8 years. In the PD-DM group, the mean duration of T2DM was 12.4 ± 6.8 years, and T2DM was diagnosed 9.2 ± 6.8 years before the PD onset. The PD-DM group had an older age of PD onset (5.9 ± 1.6 year, p < 0.001). Conclusions: Patients with PD-DM had an older age at PD onset, suggesting a potential T2DM role in delaying the age of disease onset.